Latest Ratios: P/E Ratio -51.3x · EV/EBITDA 31.8x · ROE 2.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $900M | $2.2B | $1.2B | $728M | $485M | $793M | $894M | $1.0B | $1.0B | $654M | $629M |
| Enterprise Value | $1.1B | $2.4B | $1.5B | $1.0B | $803M | $1.1B | $1.1B | $1.2B | $1.2B | $840M | $643M |
| P/E Ratio → | -51.34 | 217.19 | — | — | — | — | — | 600.67 | — | 174.09 | 59.84 |
| P/S Ratio | 1.87 | 4.87 | 3.07 | 2.06 | 1.55 | 2.65 | 3.53 | 3.71 | 3.93 | 3.45 | 3.48 |
| P/B Ratio | 1.95 | 4.80 | 4.31 | 2.59 | 1.71 | 2.64 | 2.72 | 3.59 | 3.76 | 2.34 | 3.01 |
| P/FCF | — | — | 107.85 | 63.93 | — | — | 177.33 | 132.25 | 252.35 | 173.90 | 51.12 |
| P/OCF | 23.60 | 56.41 | 53.59 | 38.70 | — | — | 72.27 | 64.80 | 104.58 | 60.56 | 31.87 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.39 | 3.86 | 2.90 | 2.56 | 3.68 | 4.54 | 4.48 | 4.62 | 4.43 | 3.56 |
| EV / EBITDA | 31.80 | 48.33 | 23.78 | 35.67 | 28.02 | 34.28 | 37.95 | 34.98 | 44.35 | 47.41 | 21.28 |
| EV / EBIT | 42.14 | 57.50 | 56.06 | 276.83 | 247.74 | 534.14 | — | 74.83 | 100.35 | 99.49 | 38.02 |
| EV / FCF | — | — | 135.80 | 90.20 | — | — | 228.10 | 159.51 | 296.81 | 223.25 | 52.28 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.3% | 61.3% | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% | 66.3% | 65.8% | 67.8% | 65.9% |
| Operating Margin | 6.1% | 6.1% | 10.0% | 1.6% | 2.0% | 2.7% | 1.0% | 6.2% | 3.5% | 4.2% | 12.1% |
| Net Profit Margin | 2.2% | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.6% | -1.4% | 2.0% | 6.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.7% | 2.7% | -4.8% | -10.8% | -6.6% | -4.7% | -5.4% | 0.6% | -1.4% | 1.5% | 5.9% |
| ROA | 1.2% | 1.2% | -1.7% | -3.9% | -2.5% | -1.9% | -2.4% | 0.3% | -0.7% | 0.8% | 4.3% |
| ROIC | 3.2% | 3.2% | 5.0% | 0.7% | 0.8% | 1.0% | 0.3% | 2.7% | 1.5% | 1.7% | 9.8% |
| ROCE | 3.6% | 3.6% | 5.3% | 0.8% | 0.8% | 1.1% | 0.4% | 3.1% | 1.7% | 1.9% | 9.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.65 | 0.65 | 1.31 | 1.27 | 1.25 | 1.20 | 0.97 | 0.86 | 0.81 | 0.81 | 0.34 |
| Debt / EBITDA | 5.94 | 5.94 | 5.74 | 12.43 | 12.46 | 11.28 | 10.48 | 6.93 | 8.16 | 12.78 | 2.37 |
| Net Debt / Equity | — | 0.51 | 1.12 | 1.06 | 1.12 | 1.02 | 0.78 | 0.74 | 0.66 | 0.67 | 0.07 |
| Net Debt / EBITDA | 4.62 | 4.62 | 4.90 | 10.39 | 11.08 | 9.57 | 8.45 | 5.98 | 6.64 | 10.48 | 0.47 |
| Debt / FCF | — | — | 27.95 | 26.27 | — | — | 50.78 | 27.26 | 44.46 | 49.34 | 1.16 |
| Interest Coverage | 1.56 | 1.56 | 0.78 | 0.15 | 0.18 | 0.12 | -0.03 | 1.11 | 0.77 | 1.73 | 5.56 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.99 | 2.99 | 4.34 | 4.85 | 4.98 | 5.51 | 3.88 | 4.15 | 5.19 | 4.18 | 4.89 |
| Quick Ratio | 2.08 | 2.08 | 3.15 | 3.43 | 3.48 | 3.80 | 2.67 | 2.97 | 3.87 | 3.09 | 4.02 |
| Cash Ratio | 0.64 | 0.64 | 0.80 | 1.02 | 0.79 | 1.22 | 1.02 | 0.75 | 1.20 | 0.95 | 1.90 |
| Asset Turnover | — | 0.50 | 0.49 | 0.45 | 0.41 | 0.38 | 0.32 | 0.46 | 0.46 | 0.32 | 0.57 |
| Inventory Turnover | 1.85 | 1.85 | 1.75 | 1.52 | 1.49 | 1.32 | 1.17 | 1.76 | 1.98 | 1.31 | 2.34 |
| Days Sales Outstanding | — | 85.75 | 80.69 | 76.44 | 80.94 | 70.97 | 70.27 | 73.81 | 71.42 | 98.98 | 60.90 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | 0.5% | — | — | — | — | — | 0.2% | — | 0.6% | 1.7% |
| FCF Yield | — | — | 0.9% | 1.6% | — | — | 0.6% | 0.8% | 0.4% | 0.6% | 2.0% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.4% | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.4% | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.1% |
| Shares Outstanding | — | $47M | $42M | $41M | $40M | $39M | $38M | $38M | $36M | $34M | $33M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AORT stock.
Artivion, Inc.'s current P/E ratio is -51.3x. The historical average is 60.0x.
Artivion, Inc.'s current EV/EBITDA is 31.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.8x.
Artivion, Inc.'s return on equity (ROE) is 2.7%. The historical average is -0.4%.
Based on historical data, Artivion, Inc. is trading at a P/E of -51.3x. Compare with industry peers and growth rates for a complete picture.
Artivion, Inc. has 61.3% gross margin and 6.1% operating margin.
Artivion, Inc.'s Debt/EBITDA ratio is 5.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Earnings miss and cash burn
Metrics are mathematically derived from official filings.
Premium Multiples Priced Against Thin Earnings
Based on reported figures, Artivion trades at 34.09x trailing EV/EBITDA and 2.04x sales, a premium that the 2.2% net margin and negative trailing P/E of -55.97 do not clearly justify on current earnings.
Traditional earnings multiples are not meaningful here because net income is negative, so the market is effectively anchoring on EV/EBITDA and sales. The 34x EBITDA multiple sits well above the medical device peer group, with AtriCure at 73.9x the only peer with a higher multiple and TransMedics near 23.9x, suggesting investors are paying for the U.S. stent-graft platform expansion rather than current cash earnings. This pricing appears to depend on successful JOTEC portfolio approvals, and investors should monitor whether the multiple compresses if that timeline slips.
Operating Margin Compression Erodes Earning Power
As reported in quarterly statements, Artivion's operating margin fell from 11.1% in 2025Q3 to 2.4% in 2026Q3, while gross margin compressed roughly 420 basis points to 61.4% over the same span.
Gross margin has held within a 60% to 66% band, so the deterioration is concentrated below the gross line, where SG&A absorbed roughly half of revenue in the latest quarter. This suggests the earnings problem is one of operating cost structure rather than pricing or product mix alone. The gap between a 2.4% operating margin and a -6.4% net margin indicates below-the-line items are also weighing on reported profit, warranting investigation of the specific drivers.
Returns Near Zero With Goodwill Weighing
Based on Artivion's reported figures, ROIC stood at 0.3% in 2026Q3 and ROE at -1.8%, far below the 18.8% ROIC and 28.4% ROE reported by TransMedics, indicating little value creation on invested capital.
Returns on capital have been low across the ten-quarter window, peaking at only 1.5% ROIC in 2025Q3, which is weak for a device company with high gross margins. Goodwill of roughly $345M from acquisitions sits inside the invested capital base, so the low ROIC may reflect acquisition premiums not yet translating into operating profit. Investors should evaluate whether the JOTEC-related capital deployment can lift returns toward a level justifying the current enterprise value.
Debt Rebuild Reverses Deleveraging Progress
According to reported balance sheets, total debt rose from $258.2M in 2026Q1 to $407.0M in 2026Q3, lifting debt-to-equity to 0.91 while interest coverage fell to 0.31x, signaling weaker debt service comfort.
Coverage of 0.31x means operating earnings in 2026Q3 covered only about a third of interest expense, a level that merits close monitoring regardless of the still-moderate debt-to-equity ratio. The reversal of the earlier debt paydown suggests renewed borrowing, which may reflect funding needs from negative free cash flow. Refinancing terms and covenant headroom are not disclosed in the supplied data, so their risk cannot be assessed here.
Strong Current Ratio Masks Thin Cash Position
Based on reported figures, the 4.42 current ratio and 3.02 quick ratio in 2026Q3 look comfortable, yet cash of $48.4M against $407.0M of total debt suggests limited cash cushion for servicing obligations.
The high current ratio is supported largely by receivables and inventory rather than cash, so the quick ratio of 3.02 remains strong but depends on collection of an 81-day DSO. Inventory is tied up for roughly 202 days, meaning a stress scenario in which collections slow could quickly erode working capital flexibility. The liquidity cushion therefore appears adequate on paper but may be less resilient than the ratios imply under severe stress.
Long Cash Cycle Ties Up Working Capital
As reported in quarterly figures, Artivion's cash conversion cycle reached 246 days in 2026Q3, with inventory days of 202 far exceeding the 37-day DPO, leaving substantial working capital absorbed by inventory.
A cash conversion cycle near 250 days is structurally long, driven primarily by slow-turning inventory typical of preservation and implant businesses. The thin payables cushion means the company funds most of its operations rather than leaning on suppliers. Working capital drains noted in cash flow results are consistent with this inventory build, suggesting efficiency improvement would be a key lever for cash generation.
Reported Equity Growth May Overstate Balance Sheet Strength
Based on reported figures, the 0.91 debt-to-equity ratio looks moderate, but negative retained earnings and a 39.6x EBITDA leverage reading suggest headline equity strength may understate the underlying debt burden.
The apparent deleveraging from 1.31 to 0.91 debt-to-equity may reflect capital injections rather than earnings-driven strength, since retained earnings remain negative. Measured against EBITDA rather than book equity, leverage appears considerably higher, which investors may wish to weigh alongside the 0.31x interest coverage. This suggests the balance sheet could be less resilient than headline ratios imply, warranting further investigation of the debt maturity profile.